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III pattern and in them interestingly normal ECG was seen in 50 %
and in another 50 % LVHwith no strain was noted. QS pattern was
seen in 30.4 % and left atrial abnormality in 21.6 %. TYPE IV pattern
was seen in 17 patients and in which 16 patients (94.1% ) had a
characteristic V4 R wave > 20 mm with deep T inversions in pre-
cordial leads. This unique pattern of electrocardiographic findings
had a sensitivity of 93 % for TYPE IV HCM.
Conclusions: Both symmetrical and asymmetrical hypertrophy
was noted in cases of HCM with or without obstruction. In cases
with asymmetrical hypertrophy (ASH), the hypertrophy was pre-
dominantly distributed either in the upper or lower septum,
lateral wall and posterior wall. The anterior ventricular septum
was predominantly was the most frequently hypertrophied
segment of the left ventricle seen in 78.3 %, followed by posterior
part of the septum in 58.33 %, and lateral free wall in 35 %. Pos-
terior free wall was preferentially spared and was thickened in
only 5 % of the patients. Except for the classical pattern of V4 R
wave of more than 20 mm with deep T inversions in precordial
leads in 94.1 % of TYPE IV hypertrophy, no other singular echo-
cardiographic pattern seemed to be very classical for the specific
distribution of hypertrophy.
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Background: Stress cardiomyopathy (SC) is a novel cardiac syn-
drome characterized by peculiar, transient left ventricular
dysfunction in the absence of significant coronary occlusion.Ex-
acerbations of chronic medical conditions and sepsis are common
precipitants that precede the “myocardial stunning.”There is ev-
idence that inflammatory cytokines released by Escherisca coli
and lipopolysaccharide administration cause decreased cardiac
myofilament responsiveness and contractility.
Methods: The present systematic review aimed to report an
updated case series of SC precipitated by E.coli sepsis in an
attempt to summarize their demographic and clinical character-
istics. A systematic search through Medline archives accessed by
Pudmed (1950-2013) for all such case reports matching our inclu-
sion criterion was performed. Overall, four such cases were
eligible and we included our patient with SC with E.coli sepsis as
the fifth report. Demographic, clinical, electrocardiographic, and
echocardiographic characteristics were compared and evaluated.
Results: There was a greater male predominance with an average
age of 56 years. The most common ECG abnormalities were ST
segment elevation in lateral leads (40%) and anterior leads (60%).
There were no fatal outcomes in the cases reported in this anal-
ysis. The average time to achieve recovery of clinical, biochemical,
and echocardiographic abnormalities was 17 days.
Conclusion: In comparison to most cases of SC reported in liter-
ature due to other stressors, E.coli sepsis SC are younger and show
a greater male predominance. Other unique characteristics of this
subset of patients are ST segment elevation in lateral leads,
modest increase in troponin levels, and relatively faster complete
recovery. Patients in whom E.coli sepsis is the precipitating factor
of SC have a different spectrum of clinical, biochemical, and
electrocardiographic changes. A high index of clinical suspicion is
essential in the diagnosis and treatment of these patients.
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Background: Heart failure is associated with high mortality and
morbidity. Tachycardia is an important risk factor for adverse out-
comes. Betablockers are important part of heart failure manage-
ment as they reducesmortality significantly.Weassessed the effect
of heart-rate reduction by the ivabradine on outcomes in heart
failure in patients in whom beta blockers were contraindicated.
Methods: Patients were eligible for participation in this study if
they had symptomatic heart failure with left-ventricular ejection
fraction of 35% or lower, were in sinus rhythm with heart rate
more than 75 bpm who were admitted with aggravation of
symptoms, and beta blockers were contraindicated. Patients were
given ivabradine titrated to a maximum of 7$5 mg twice daily or
matching placebo The primary endpoint was the composite of
cardiovascular death or hospital admission for worsening heart
failure.
Result: We evaluated 1500 patients of heart failure from Januaury
2010 till June 2014.Out of 1500 patients, 800 patients were ineli-
gible for betablockers in view of low blood pressure. Out of rest 700
patients, 350 patients received ivabradine and 350 patients were
given placebo. 60% patients were males and rest were females.
They were followed for more than two years. There was no sig-
nificant difference in mortality between the two groups as 24
patients from ivabradine and 27 patients from placebo group
expired ( p - non significant). There was not much difference in
hospital admissions due to worsening of heart failure. (82 patients
from ivabradine group and 87 patients from placebo group got
admitted.), No significant side effects were noted with ivabradine.
Conclusion: There was no significant difference in mortality and
morbidity with ivabradine therapy in patients with heart failure in
whom betablockers were contraindicated. Hospitilization was
more or less same in both the groups.
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Background: Ivabradine, selective If channel blocker, has been
shown to reduce recurrent hospitalization due to worsening of
heart failure. Role of this agent on left ventricular function in
patients with ischemic heart failure is still unexplored.
Aims and objectives: This study was planned to assess the effects
of addition of ivabradine to optimal medical therapy(OMT) in
patients of ischemic heart failure with systolic dysfunction on Left
ventricular function, Exercise duration, Serum Brain Natriuretic
Peptide (BNP) levels and Health-related quality of life.
Methods: In this open-label, randomized, a total number of 158
patients of stable, ischemic heart failure were included and were
randomly assigned into OMT group (n¼80) and ivabradine group
(n¼78). Baseline assessments included assessment of Left ven-
tricular dimension and Left ventricular ejection fraction (LVEF),
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